OR WAIT null SECS
The expansion is part of a new expansion initiative aimed at increasing flexibility, efficiency, and cost-effective production.
CordenPharma Colorado announced on Nov. 25, 2020 it has completed the expansion of its solid-phase peptide synthesis (SPPS) manufacturing capacity with the addition of an extra-large 3000-L SPPS vessel.
The expansion is part of a new expansion initiative aimed at increasing flexibility, efficiency, and cost-effective production, a company press release said.
“For the first phase of this commitment, customized automated synthesizer production lines will be installed supporting fast and efficient GMP manufacturing,” CordenPharma said in the press release. “This infrastructure will further strengthen the existing manufacturing of Peptides in the low to mid-kg scale range by complementing the current state-of-the art large-scale manufacturing capabilities at CordenPharma Colorado.”
The company will also supply peptide APIs for injectable drug products at their Italian facility, CordenPharma Caponago, as part of the initiative.